跨国公司频频牵手国内药企开发新药

Multinational Pharmaceutical Companies Join Hands with Domestic Pharmaceutical Companies in Drug R&D

跨国企业与国内机构联合开发并不罕有,本刊之前报道过的沪亚从微星手中买走做到临床Ⅰ期的西达苯胺就是其中一例。如今,同是抗肿瘤药,萘莫柔比星却反其道而行之,在国外做完临床Ⅱ期被抛到中国找买主,对于中国企业来说,这是不是一个绝佳的机会?然而,卖方"非价高者得"的表态似乎证明,他们更看重国内企业继续研发的实力。

Codevelopment between multinational pharmaceutical companies and domestic pharmaceutical companies is not a rare view,China Prescription Drug has reported Huya Bioscience International licensed exclusively licensed worldwide rights outside China to the cancer compound chidamide from Shenzhen Chipscreen Biosciences Ltd. Today,codevelopment of nemorubicin hydrochloride takes an opposite way,after completion of phase II clinical trial,it came to China to find a buyer. For domestic pharmaceutical companies,is it an excellent opportunity? However,the statement of non-highest bidder from the seller shows that the seller places more importance on the strength of domestic enterprises to continue to develop.